May Moonan

2.3k total citations
3 papers, 71 citations indexed

About

May Moonan is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, May Moonan has authored 3 papers receiving a total of 71 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Oncology, 2 papers in Cancer Research and 1 paper in Surgery. Recurrent topics in May Moonan's work include HER2/EGFR in Cancer Research (2 papers), Breast Cancer Treatment Studies (2 papers) and Advanced Breast Cancer Therapies (1 paper). May Moonan is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Breast Cancer Treatment Studies (2 papers) and Advanced Breast Cancer Therapies (1 paper). May Moonan collaborates with scholars based in United Kingdom. May Moonan's co-authors include Hugh L. Davis, A Bagust, Anne Armstrong, Angela Boland, Y Dündar, Nigel Fleeman, M Blundell, J Oyee, Nicky Thorp and Mohammed A. Ghatei and has published in prestigious journals such as Clinical Endocrinology and Health Technology Assessment.

In The Last Decade

May Moonan

3 papers receiving 68 citations

Peers

May Moonan
Comparison fields: 5 of 34
  • Oncology 29
  • Endocrinology, Diabetes and Metabolism 17
  • Surgery 13
  • Pharmacology 10
  • Radiology, Nuclear Medicine and Imaging 10
Replace Lamya Hamad with:
Lamya Hamad United States
Kai Su China
T Hada Japan
Zong-Li Yuan China
Mehrdad Rabiee Rad Iran
Gustavo Vasconcelos Alves Brazil
Rebecca Wu Canada
Brett Vanderwerff United States
Bradley Godfrey United States
Lamya Hamad United States View profile →
Citations per field, relative to May Moonan
May Moonan · 1×
Citations per year, relative to May Moonan
May Moonan · 1×

Countries citing papers authored by May Moonan

Since Specialization
Citations

This map shows the geographic impact of May Moonan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May Moonan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May Moonan more than expected).

Fields of papers citing papers by May Moonan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May Moonan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May Moonan. The network helps show where May Moonan may publish in the future.

Co-authorship network of co-authors of May Moonan

This figure shows the co-authorship network connecting the top 25 collaborators of May Moonan. A scholar is included among the top collaborators of May Moonan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May Moonan. May Moonan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

3 of 3 papers shown
# Work Indexed citations
1 50
2
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancr which over-expresses HER2
2
3 19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026